Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. (ProComD)
Sponsor: Ferring Pharmaceuticals
A observational or N/A phase clinical study on Advanced Prostate Cancer, this trial is completed. The trial is conducted by Ferring Pharmaceuticals and has accumulated 12 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Aug 2019 — Jan 2021 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Apr 2019 — Aug 2019 [monthly]
Active Not Recruiting
▶ Show 7 earlier versions
-
Feb 2019 — Apr 2019 [monthly]
Active Not Recruiting
-
Nov 2018 — Feb 2019 [monthly]
Active Not Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Jun 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Jun 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ferring Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .